Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company pioneering T cell-engaging bispecific antibody therapies for solid tumors. This page serves as the definitive source for verified news and official updates about the company's innovative oncology pipeline, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated updates on key programs like CTIM-76 (targeting CLDN6+ cancers) and CT-95/CT-202 bispecific antibodies. All content is sourced directly from company filings and press releases, ensuring reliability for those monitoring developments in precision cancer immunotherapy.
Our news coverage focuses on three critical areas: Clinical Trial Advancements (Phase 1/2 updates, patient enrollment), Regulatory Progress (FDA communications, trial design approvals), and Strategic Collaborations (research partnerships, intellectual property developments). Each update is contextualized to show its significance within the broader oncology treatment landscape.
Bookmark this page for streamlined access to Context Therapeutics' latest developments in bispecific antibody research. Check back regularly for real-time updates on their mission to transform care for hormone-driven and treatment-resistant cancers.
Context Therapeutics Inc. (NASDAQ:CNTX) is advancing therapies for solid tumors, focusing on Claudin 6 (CLDN6). The company is developing CTIM-76, a bispecific antibody targeting CLDN6, estimated to potentially treat 62,500 metastatic cancer patients in the U.S. CLDN6's unique presence in specific cancers, like ovarian and lung cancers, enables targeted T cell activation, minimizing damage to healthy cells. Context aims to address the limitations of current treatments, which can harm both cancerous and healthy cells, causing significant side effects. The company is set to present preclinical data at the AACR Annual Meeting on April 17 and plans to submit an IND filing by Q1 2024 for clinical trials. For more details, visit www.contexttherapeutics.com.
Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will participate in two virtual investor conferences in April 2023. The details are: Diamond Equity Emerging Growth Invitational Investor Conference presentation on April 5 at 9:40 a.m. ET, and 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET, where one-on-one meetings will also occur. Context is focused on developing CTIM-76, a bispecific antibody targeting CLDN6-positive tumors, currently in preclinical development. For further information, visit contexttherapeutics.com.
Context Therapeutics Inc. (Nasdaq: CNTX) announced a strategic shift prioritizing the development of CTIM-76, a Claudin 6 (CLDN6) bispecific antibody to treat solid tumors, while discontinuing the ONA-XR program. The company reported a net loss of $14.8 million for 2022, an increase from $10.5 million in 2021. Cash and equivalents at year-end were approximately $35.5 million, expected to fund operations into late 2024. The IND application for CTIM-76 is anticipated in Q1 2024. Preclinical data will be presented at the AACR Annual Meeting 2023. The decision to cease ONA-XR development was influenced by challenging market conditions and study findings.